High-cost Drugs | GenomeWeb

High-cost Drugs

The UK plans to boost its spending on expensive cancer drugs by around £160 million ($264 million) over the next two years, increasing its outlay from £200 million a year to £280 million per year, but the government also wants to increase its scrutiny of how well these drugs work for the cost.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.